Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) EBITDA: 2009-2024

Historic EBITDA for OptimizeRx (OPRX) over the last 16 years, with FY2024 value amounting to -$13.6 million.

  • OptimizeRx's EBITDA rose 12394.3% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 12393.16%. This contributed to the annual value of -$13.6 million for FY2024, which is 4831.19% up from last year.
  • OptimizeRx's EBITDA amounted to -$13.6 million in FY2024, which was up 4831.19% from -$26.3 million recorded in FY2023.
  • Over the past 5 years, OptimizeRx's EBITDA peaked at $466460.0 during FY2021, and registered a low of -$26.3 million during FY2023.
  • Moreover, its 5-year median value for EBITDA was -$12.2 million (2022), whereas its average is -$10.7 million.
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 12286.44% in 2021, then crashed by 271651.87% in 2022.
  • OptimizeRx's EBITDA (Annual) stood at -$2.0 million in 2020, then soared by 122.86% to $466460.0 in 2021, then plummeted by 2716.52% to -$12.2 million in 2022, then tumbled by 115.5% to -$26.3 million in 2023, then soared by 48.31% to -$13.6 million in 2024.
  • Its EBITDA stands at -$13.6 million for FY2024, versus -$26.3 million for FY2023 and -$12.2 million for FY2022.